What is Bellicum Pharmaceuticals, Inc. (BLCM)?

Bellicum Pharmaceuticals, Inc. (BLCM) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of BLCM?

The current price of BLCM is $0.07. Prices are updated in real time on Stocks360.

What is BLCM's price-to-earnings (PE) ratio?

BLCM's trailing twelve-month PE ratio is -0.09, based on current price and earnings per share data available on Stocks360.

What is BLCM's market capitalization?

BLCM's market capitalization is $778,326.00, placing it in the small-cap tier.

Bellicum Pharmaceuticals, Inc. (BLCM)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.07

Market Cap

$778.33K

PE (TTM)

-0.09

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.38

Day Range

$0.07 – $0.09

52-wk Range

$0.06 – $1.31

Avg Volume

N/A

Volume

6.06K

Bellicum Pharmaceuticals, Inc. (BLCM) is a publicly traded company in the Healthcare sector. Latest price: $0.07. Market cap $778.33K. Trailing PE -0.09. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 10, 2023

EPS $-0.24 vs est. $-0.29

Beat by $0.05

Proprietary Signals

Signal snapshot temporarily unavailable.

About Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations. BPX-601, an autologous therapy, targets solid tumors that exhibit the prostate stem cell antigen. Additionally, BPX-603, a dual-switch GoCAR-T treatment, is being investigated for solid tumors characterized by the human epidermal growth factor receptor 2 (HER2) antigens. The company also features Rivo-cel, an allogeneic T cell therapy designed to improve patient prognoses in cases of leukemias, lymphomas, and various inherited blood disorders. Bellicum maintains strategic partnerships and licensing arrangements with several entities, including Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Established in 2004, the company's corporate headquarters are located in Houston, Texas.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.09×
P/S (TTM)	0.52×
P/B	1.14×
PEG	0.00×
P/FCF (TTM)	-0.03×
EV / EBITDA	0.84×
EV / Sales	-14.04×
Earnings Yield	-1083.70%
Free Cash Flow Yield	-3315.32%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$21.06M
Net Income (TTM)	-$8.43M
Free Cash Flow (TTM)	-$25.80M
Net Debt	-$21.84M
Working Capital	$20.03M
Gross Margin	100.00%
Operating Margin	-1798.73%
Net Margin	-1664.87%
Return on Equity	-189.12%
Return on Invested Capital	-134.56%